# SJMB12 (NCT01878617)

> A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

No report yet. It can be ordered.

- Drugs tested: vismodegib plus cyclophosphamide plus cisplatin plus vincristine; pemetrexed plus gemcitabine plus cyclophosphamide plus cisplatin; cyclophosphamide plus cisplatin plus vincristine
- Indication: newly diagnosed medulloblastoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01878617
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: St. Jude Children's Research Hospital
- Conditions: Medulloblastoma
- Interventions: Craniospinal Irradiation with boost to the primary tumor site; Cyclophosphamide; Cisplatin; Vincristine; Vismodegib; Pemetrexed; Gemcitabine; Aerobic Training; Neurocognitive Remediation
- Enrollment: 660
- Primary outcome: Progression-free Survival in Stratum W1
- Primary outcome: Progression-free Survival in Stratum N1
- Primary outcome: Progression-free Survival in Stratum S1 Skeletally Mature Cohort
- Primary outcome: Change in VO2 Peak Value
- Primary outcome: Change in Spatial Span Backward Standard Score

## Indexed commentary on SJMB12 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X
- 1 YouTube video

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=sjmb12-nct01878617